A variety of genes thatplay pivotal roles in lipid metabolism, such as low-density lipoprotein receptor(LDLR), PCSK9, angiopoietin-like protein 3(ANGPTL3), apolipoprotein C3 (APOC3), and lipoprotein(a) (LPA),have been strategically targeted for the treatment of dyslipidemia,showcasing the versatility and promise of gene editing in this field. This evidence concerns the gene LPA and metabolic syndrome.